- Home
- APRE vs KPRX Comparison
APRE vs KPRX Comparison
Compare APRE & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- KPRX
- Stock Information
- Founded
- APRE 2006
- KPRX 1998
- Country
- APRE United States
- KPRX United States
- Employees
- APRE N/A
- KPRX N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- APRE Health Care
- KPRX Health Care
- Exchange
- APRE Nasdaq
- KPRX Nasdaq
- Market Cap
- APRE 9.4M
- KPRX 9.2M
- IPO Year
- APRE 2019
- KPRX N/A
- Fundamental
- Price
- APRE $1.54
- KPRX $2.66
- Analyst Decision
- APRE Strong Buy
- KPRX Strong Buy
- Analyst Count
- APRE 1
- KPRX 1
- Target Price
- APRE $20.00
- KPRX $10.00
- AVG Volume (30 Days)
- APRE 34.4K
- KPRX 51.3K
- Earning Date
- APRE 11-06-2025
- KPRX 11-07-2025
- Dividend Yield
- APRE N/A
- KPRX N/A
- EPS Growth
- APRE N/A
- KPRX N/A
- EPS
- APRE N/A
- KPRX N/A
- Revenue
- APRE $841,012.00
- KPRX N/A
- Revenue This Year
- APRE N/A
- KPRX N/A
- Revenue Next Year
- APRE N/A
- KPRX N/A
- P/E Ratio
- APRE N/A
- KPRX N/A
- Revenue Growth
- APRE N/A
- KPRX N/A
- 52 Week Low
- APRE $1.41
- KPRX $2.25
- 52 Week High
- APRE $5.01
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- APRE 43.27
- KPRX 46.48
- Support Level
- APRE $1.49
- KPRX $2.60
- Resistance Level
- APRE $1.66
- KPRX $2.80
- Average True Range (ATR)
- APRE 0.08
- KPRX 0.12
- MACD
- APRE 0.00
- KPRX -0.00
- Stochastic Oscillator
- APRE 27.00
- KPRX 19.09
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.